CA2828433C - Diagnostic antibody assay - Google Patents

Info

Publication number

CA2828433C

CA2828433C CA2828433A CA2828433A CA2828433C CA 2828433 C CA2828433 C CA 2828433C CA 2828433 A CA2828433 A CA 2828433A CA 2828433 A CA2828433 A CA 2828433A CA 2828433 C CA2828433 C CA 2828433C

Authority

CA

Canada

Prior art keywords

antibody

disease

alzheimer

antigen

beta

Prior art date

2011-03-16

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Active

Links

• Espacenet
• Global Dossier
• CIPO
• Discuss

• 238000003556 assay Methods 0.000 title abstract description 20
• 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 149
• 238000003745 diagnosis Methods 0.000 claims abstract description 16
• 108090000765 processed proteins & peptides Proteins 0.000 claims description 139
• 210000004408 hybridoma Anatomy 0.000 claims description 123
• 230000027455 binding Effects 0.000 claims description 75
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 58
• 239000012634 fragment Substances 0.000 claims description 50
• 239000000427 antigen Substances 0.000 claims description 47
• 108091007433 antigens Proteins 0.000 claims description 47
• 102000036639 antigens Human genes 0.000 claims description 47
• 239000000203 mixture Substances 0.000 claims description 42
• ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 claims description 38
• 230000004770 neurodegeneration Effects 0.000 claims description 37
• 208000010877 cognitive disease Diseases 0.000 claims description 35
• 239000003112 inhibitor Substances 0.000 claims description 35
• 208000027061 mild cognitive impairment Diseases 0.000 claims description 32
• 208000017227 ADan amyloidosis Diseases 0.000 claims description 31
• 201000000194 ITM2B-related cerebral amyloid angiopathy 2 Diseases 0.000 claims description 31
• 238000001514 detection method Methods 0.000 claims description 31
• 208000023697 ABri amyloidosis Diseases 0.000 claims description 30
• 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 claims description 30
• 230000015572 biosynthetic process Effects 0.000 claims description 29
• 208000015122 neurodegenerative disease Diseases 0.000 claims description 21
• 201000010374 Down Syndrome Diseases 0.000 claims description 20
• 102000003642 glutaminyl-peptide cyclotransferase Human genes 0.000 claims description 18
• 108010081484 glutaminyl-peptide cyclotransferase Proteins 0.000 claims description 18
• 238000010494 dissociation reaction Methods 0.000 claims description 15
• 230000005593 dissociations Effects 0.000 claims description 15
• 229940088623 biologically active substance Drugs 0.000 claims description 10
• 239000002773 nucleotide Substances 0.000 claims description 10
• 125000003729 nucleotide group Chemical group 0.000 claims description 10
• 238000009007 Diagnostic Kit Methods 0.000 claims description 9
• 239000008194 pharmaceutical composition Substances 0.000 claims description 9
• 238000002405 diagnostic procedure Methods 0.000 claims description 8
• 230000001900 immune effect Effects 0.000 claims description 8
• 239000003937 drug carrier Substances 0.000 claims description 7
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
• 239000003085 diluting agent Substances 0.000 claims description 6
• 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims description 6
• 238000000338 in vitro Methods 0.000 claims description 5
• 239000007790 solid phase Substances 0.000 claims description 4
• 230000002265 prevention Effects 0.000 claims description 2
• 125000003275 alpha amino acid group Chemical group 0.000 claims 3
• 206010002022 amyloidosis Diseases 0.000 abstract description 31
• 210000004027 cell Anatomy 0.000 description 153
• 108090000623 proteins and genes Proteins 0.000 description 58
• 235000018102 proteins Nutrition 0.000 description 57
• 102000004169 proteins and genes Human genes 0.000 description 57
• 238000000034 method Methods 0.000 description 55
• 239000000523 sample Substances 0.000 description 54
• 238000000111 isothermal titration calorimetry Methods 0.000 description 53
• 238000002965 ELISA Methods 0.000 description 50
• 238000004113 cell culture Methods 0.000 description 47
• 239000012228 culture supernatant Substances 0.000 description 43
• 108020004774 Alkaline Phosphatase Proteins 0.000 description 39
• 102000002260 Alkaline Phosphatase Human genes 0.000 description 39
• 239000000872 buffer Substances 0.000 description 39
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 38
• 201000010099 disease Diseases 0.000 description 35
• 230000016784 immunoglobulin production Effects 0.000 description 32
• 239000000243 solution Substances 0.000 description 31
• 238000010828 elution Methods 0.000 description 30
• 101710120037 Toxin CcdB Proteins 0.000 description 29
• 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 28
• 210000004556 brain Anatomy 0.000 description 27
• YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 26
• 239000007924 injection Substances 0.000 description 26
• 238000002347 injection Methods 0.000 description 26
• 230000012010 growth Effects 0.000 description 25
• 238000005259 measurement Methods 0.000 description 25
• 229960002685 biotin Drugs 0.000 description 23
• 239000011616 biotin Substances 0.000 description 23
• 210000002966 serum Anatomy 0.000 description 23
• 239000012091 fetal bovine serum Substances 0.000 description 22
• 238000000746 purification Methods 0.000 description 21
• 238000012360 testing method Methods 0.000 description 20
• 238000010790 dilution Methods 0.000 description 19
• 239000012895 dilution Substances 0.000 description 19
• 238000011534 incubation Methods 0.000 description 19
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 18
• 208000002780 macular degeneration Diseases 0.000 description 18
• 239000002609 medium Substances 0.000 description 18
• ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 17
• 208000035474 group of disease Diseases 0.000 description 17
• 239000000758 substrate Substances 0.000 description 17
• 150000001413 amino acids Chemical class 0.000 description 16
• 229930182816 L-glutamine Natural products 0.000 description 15
• DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 15
• 238000007413 biotinylation Methods 0.000 description 15
• 230000006287 biotinylation Effects 0.000 description 15
• 238000006243 chemical reaction Methods 0.000 description 15
• 239000004017 serum-free culture medium Substances 0.000 description 15
• 208000037259 Amyloid Plaque Diseases 0.000 description 14
• 102000004190 Enzymes Human genes 0.000 description 14
• 108090000790 Enzymes Proteins 0.000 description 14
• 229940088598 enzyme Drugs 0.000 description 14
• 238000002474 experimental method Methods 0.000 description 14
• 239000012528 membrane Substances 0.000 description 14
• 238000003786 synthesis reaction Methods 0.000 description 14
• 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 13
• 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 13
• 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 13
• 235000020958 biotin Nutrition 0.000 description 13
• 230000010261 cell growth Effects 0.000 description 13
• 210000001519 tissue Anatomy 0.000 description 13
• 108010047041 Complementarity Determining Regions Proteins 0.000 description 12
• 206010012289 Dementia Diseases 0.000 description 12
• 241000699666 Mus <mouse, genus> Species 0.000 description 12
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
• 239000003795 chemical substances by application Substances 0.000 description 12
• 238000000502 dialysis Methods 0.000 description 12
• 230000003993 interaction Effects 0.000 description 12
• ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 12
• 108010001336 Horseradish Peroxidase Proteins 0.000 description 11
• 108060003951 Immunoglobulin Proteins 0.000 description 11
• 201000002832 Lewy body dementia Diseases 0.000 description 11
• 238000010521 absorption reaction Methods 0.000 description 11
• 230000002378 acidificating effect Effects 0.000 description 11
• 230000009260 cross reactivity Effects 0.000 description 11
• 102000018358 immunoglobulin Human genes 0.000 description 11
• 210000004379 membrane Anatomy 0.000 description 11
• 239000012071 phase Substances 0.000 description 11
• 239000012146 running buffer Substances 0.000 description 11
• 239000011534 wash buffer Substances 0.000 description 11
• 108010090849 Amyloid beta-Peptides Proteins 0.000 description 10
• 102000013455 Amyloid beta-Peptides Human genes 0.000 description 10
• 102000009091 Amyloidogenic Proteins Human genes 0.000 description 10
• 108010048112 Amyloidogenic Proteins Proteins 0.000 description 10
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
• 208000009829 Lewy Body Disease Diseases 0.000 description 10
• 239000012491 analyte Substances 0.000 description 10
• 238000004458 analytical method Methods 0.000 description 10
• 150000001875 compounds Chemical class 0.000 description 10
• 238000000151 deposition Methods 0.000 description 10
• 230000008021 deposition Effects 0.000 description 10
• 230000008569 process Effects 0.000 description 10
• 230000002829 reductive effect Effects 0.000 description 10
• 238000002211 ultraviolet spectrum Methods 0.000 description 10
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
• 208000023769 AA amyloidosis Diseases 0.000 description 9
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 9
• 108010021625 Immunoglobulin Fragments Proteins 0.000 description 9
• 102000008394 Immunoglobulin Fragments Human genes 0.000 description 9
• 206010039811 Secondary amyloidosis Diseases 0.000 description 9
• 230000035508 accumulation Effects 0.000 description 9
• 238000009825 accumulation Methods 0.000 description 9
• 239000012148 binding buffer Substances 0.000 description 9
• 230000001419 dependent effect Effects 0.000 description 9
• 239000003814 drug Substances 0.000 description 9
• 238000002360 preparation method Methods 0.000 description 9
• QAPSNMNOIOSXSQ-YNEHKIRRSA-N 1-[(2r,4s,5r)-4-[tert-butyl(dimethyl)silyl]oxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O[Si](C)(C)C(C)(C)C)C1 QAPSNMNOIOSXSQ-YNEHKIRRSA-N 0.000 description 8
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
• 230000000903 blocking effect Effects 0.000 description 8
• 230000001149 cognitive effect Effects 0.000 description 8
• 230000000694 effects Effects 0.000 description 8
• 239000001963 growth medium Substances 0.000 description 8
• 238000003364 immunohistochemistry Methods 0.000 description 8
• 229940043131 pyroglutamate Drugs 0.000 description 8
• 241000894007 species Species 0.000 description 8
• 238000001228 spectrum Methods 0.000 description 8
• 208000018282 ACys amyloidosis Diseases 0.000 description 7
• 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 7
• 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 description 7
• 208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 description 7
• 206010025421 Macule Diseases 0.000 description 7
• DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 7
• 238000001042 affinity chromatography Methods 0.000 description 7
• 206010064930 age-related macular degeneration Diseases 0.000 description 7
• 238000001142 circular dichroism spectrum Methods 0.000 description 7
• 238000004519 manufacturing process Methods 0.000 description 7
• 239000000463 material Substances 0.000 description 7
• 229920001184 polypeptide Polymers 0.000 description 7
• 238000010186 staining Methods 0.000 description 7
• 239000006228 supernatant Substances 0.000 description 7
• HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
• 206010065040 AIDS dementia complex Diseases 0.000 description 6
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
• 201000004569 Blindness Diseases 0.000 description 6
• 241000283690 Bos taurus Species 0.000 description 6
• 102100021943 C-C motif chemokine 2 Human genes 0.000 description 6
• 206010007509 Cardiac amyloidosis Diseases 0.000 description 6
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
• 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 6
• 241001465754 Metazoa Species 0.000 description 6
• 208000018737 Parkinson disease Diseases 0.000 description 6
• 230000002776 aggregation Effects 0.000 description 6
• 238000004220 aggregation Methods 0.000 description 6
• 238000011091 antibody purification Methods 0.000 description 6
• 210000004369 blood Anatomy 0.000 description 6
• 239000008280 blood Substances 0.000 description 6
• 239000006285 cell suspension Substances 0.000 description 6
• 230000008859 change Effects 0.000 description 6
• 239000003153 chemical reaction reagent Substances 0.000 description 6
• 238000010168 coupling process Methods 0.000 description 6
• 230000037029 cross reaction Effects 0.000 description 6
• 230000007423 decrease Effects 0.000 description 6
• 201000011523 endocrine gland cancer Diseases 0.000 description 6
• 230000006870 function Effects 0.000 description 6
• 229930195712 glutamate Natural products 0.000 description 6
• 230000002209 hydrophobic effect Effects 0.000 description 6
• 238000012744 immunostaining Methods 0.000 description 6
• 201000010901 lateral sclerosis Diseases 0.000 description 6
• 239000003446 ligand Substances 0.000 description 6
• 208000005264 motor neuron disease Diseases 0.000 description 6
• 201000006417 multiple sclerosis Diseases 0.000 description 6
• 230000007505 plaque formation Effects 0.000 description 6
• 201000002212 progressive supranuclear palsy Diseases 0.000 description 6
• 238000011002 quantification Methods 0.000 description 6
• 238000012216 screening Methods 0.000 description 6
• 229910000162 sodium phosphate Inorganic materials 0.000 description 6
• 239000002904 solvent Substances 0.000 description 6
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 6
• 238000010175 APPswe/PSEN1dE9 Methods 0.000 description 5
• 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 5
• WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 5
• 241000124008 Mammalia Species 0.000 description 5
• 241001529936 Murinae Species 0.000 description 5
• 241000204031 Mycoplasma Species 0.000 description 5
• 208000012902 Nervous system disease Diseases 0.000 description 5
• 208000025966 Neurological disease Diseases 0.000 description 5
• 241000283973 Oryctolagus cuniculus Species 0.000 description 5
• 229920002684 Sepharose Polymers 0.000 description 5
• 108010090804 Streptavidin Proteins 0.000 description 5
• 239000007983 Tris buffer Substances 0.000 description 5
• 235000001014 amino acid Nutrition 0.000 description 5
• 229940024606 amino acid Drugs 0.000 description 5
• 230000000875 corresponding effect Effects 0.000 description 5
• 230000008878 coupling Effects 0.000 description 5
• 238000005859 coupling reaction Methods 0.000 description 5
• 229940079593 drug Drugs 0.000 description 5
• 230000004438 eyesight Effects 0.000 description 5
• 210000001320 hippocampus Anatomy 0.000 description 5
• 230000003834 intracellular effect Effects 0.000 description 5
• 108091005601 modified peptides Proteins 0.000 description 5
• 235000019799 monosodium phosphate Nutrition 0.000 description 5
• 238000005457 optimization Methods 0.000 description 5
• 102000013415 peroxidase activity proteins Human genes 0.000 description 5
• 108040007629 peroxidase activity proteins Proteins 0.000 description 5
• 238000003118 sandwich ELISA Methods 0.000 description 5
• 238000000926 separation method Methods 0.000 description 5
• 239000012679 serum free medium Substances 0.000 description 5
• AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 5
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
• 238000000870 ultraviolet spectroscopy Methods 0.000 description 5
• 230000004393 visual impairment Effects 0.000 description 5
• -1 /3-sheet breakers Substances 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 102100034871 C-C motif chemokine 8 Human genes 0.000 description 4
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
• WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Natural products C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
• XNSAINXGIQZQOO-UHFFFAOYSA-N L-pyroglutamyl-L-histidyl-L-proline amide Natural products NC(=O)C1CCCN1C(=O)C(NC(=O)C1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-UHFFFAOYSA-N 0.000 description 4
• 101710122864 Major tegument protein Proteins 0.000 description 4
• 102100031545 Microsomal triglyceride transfer protein large subunit Human genes 0.000 description 4
• 101710148592 PTS system fructose-like EIIA component Proteins 0.000 description 4
• 101710169713 PTS system fructose-specific EIIA component Proteins 0.000 description 4
• 229920001213 Polysorbate 20 Polymers 0.000 description 4
• 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 4
• 101710199973 Tail tube protein Proteins 0.000 description 4
• 239000000627 Thyrotropin-Releasing Hormone Substances 0.000 description 4
• 102400000336 Thyrotropin-releasing hormone Human genes 0.000 description 4
• 101800004623 Thyrotropin-releasing hormone Proteins 0.000 description 4
• 230000002159 abnormal effect Effects 0.000 description 4
• 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 4
• 230000003698 anagen phase Effects 0.000 description 4
• 230000004071 biological effect Effects 0.000 description 4
• 239000012472 biological sample Substances 0.000 description 4
• 210000004204 blood vessel Anatomy 0.000 description 4
• 210000001124 body fluid Anatomy 0.000 description 4
• 239000010839 body fluid Substances 0.000 description 4
• 239000006143 cell culture medium Substances 0.000 description 4
• 230000007910 cell fusion Effects 0.000 description 4
• 210000000170 cell membrane Anatomy 0.000 description 4
• 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
• 235000019800 disodium phosphate Nutrition 0.000 description 4
• 229910000397 disodium phosphate Inorganic materials 0.000 description 4
• 239000012153 distilled water Substances 0.000 description 4
• ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
• 238000006911 enzymatic reaction Methods 0.000 description 4
• ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 4
• WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 4
• 239000001257 hydrogen Substances 0.000 description 4
• 229910052739 hydrogen Inorganic materials 0.000 description 4
• 229940072221 immunoglobulins Drugs 0.000 description 4
• 201000008319 inclusion body myositis Diseases 0.000 description 4
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
• 230000010354 integration Effects 0.000 description 4
• 230000007246 mechanism Effects 0.000 description 4
• 230000004048 modification Effects 0.000 description 4
• 238000012986 modification Methods 0.000 description 4
• 210000002569 neuron Anatomy 0.000 description 4
• 230000007170 pathology Effects 0.000 description 4
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
• XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 4
• 238000012163 sequencing technique Methods 0.000 description 4
• 239000011780 sodium chloride Substances 0.000 description 4
• 239000000126 substance Substances 0.000 description 4
• 208000024891 symptom Diseases 0.000 description 4
• 229940034199 thyrotropin-releasing hormone Drugs 0.000 description 4
• 238000004448 titration Methods 0.000 description 4
• 238000011830 transgenic mouse model Methods 0.000 description 4
• 230000002792 vascular Effects 0.000 description 4
• 102100027211 Albumin Human genes 0.000 description 3
• 108010088751 Albumins Proteins 0.000 description 3
• 108090001008 Avidin Proteins 0.000 description 3
• 208000028698 Cognitive impairment Diseases 0.000 description 3
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
• CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 3
• 229930182566 Gentamicin Natural products 0.000 description 3
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
• 241000699670 Mus sp. Species 0.000 description 3
• 206010035148 Plague Diseases 0.000 description 3
• 239000004743 Polypropylene Substances 0.000 description 3
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 3
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
• 206010044688 Trisomy 21 Diseases 0.000 description 3
• 241000607479 Yersinia pestis Species 0.000 description 3
• 239000002253 acid Substances 0.000 description 3
• LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical compound C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 description 3
• 150000001412 amines Chemical class 0.000 description 3
• 210000003855 cell nucleus Anatomy 0.000 description 3
• 230000004663 cell proliferation Effects 0.000 description 3
• 230000002490 cerebral effect Effects 0.000 description 3
• 239000000544 cholinesterase inhibitor Substances 0.000 description 3
• 239000003593 chromogenic compound Substances 0.000 description 3
• 238000000978 circular dichroism spectroscopy Methods 0.000 description 3
• 238000003759 clinical diagnosis Methods 0.000 description 3
• 239000011248 coating agent Substances 0.000 description 3
• 238000000576 coating method Methods 0.000 description 3
• 238000011109 contamination Methods 0.000 description 3
• 208000037765 diseases and disorders Diseases 0.000 description 3
• 208000035475 disorder Diseases 0.000 description 3
• 239000003623 enhancer Substances 0.000 description 3
• 238000007710 freezing Methods 0.000 description 3
• 230000008014 freezing Effects 0.000 description 3
• 238000011065 in-situ storage Methods 0.000 description 3
• 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 3
• 238000004020 luminiscence type Methods 0.000 description 3
• 230000035772 mutation Effects 0.000 description 3
• 230000008506 pathogenesis Effects 0.000 description 3
• 239000008188 pellet Substances 0.000 description 3
• 229920001155 polypropylene Polymers 0.000 description 3
• 229920000136 polysorbate Polymers 0.000 description 3
• GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 3
• 239000002243 precursor Substances 0.000 description 3
• 239000003755 preservative agent Substances 0.000 description 3
• 230000009257 reactivity Effects 0.000 description 3
• 230000009467 reduction Effects 0.000 description 3
• 108010004093 retinal S antigen peptide M Proteins 0.000 description 3
• 238000007363 ring formation reaction Methods 0.000 description 3
• 239000012723 sample buffer Substances 0.000 description 3
• 239000001632 sodium acetate Substances 0.000 description 3
• 235000017281 sodium acetate Nutrition 0.000 description 3
• 239000012089 stop solution Substances 0.000 description 3
• 235000011149 sulphuric acid Nutrition 0.000 description 3
• 238000004114 suspension culture Methods 0.000 description 3
• 230000001225 therapeutic effect Effects 0.000 description 3
• 238000005406 washing Methods 0.000 description 3
• WZUVPPKBWHMQCE-XJKSGUPXSA-N (+)-haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@]2(O)[C@H]1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-XJKSGUPXSA-N 0.000 description 2
• NITUEMISTORFON-PPFXTMJRSA-N (2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2R)-2-aminopropanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-phenylpropanoyl]amino]propanoyl]amino]-4-oxobutanoyl]amino]-3-methylpentanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@@H](C)N)C(C)C)C(C)C)C1=CC=CC=C1 NITUEMISTORFON-PPFXTMJRSA-N 0.000 description 2
• GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
• NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 description 2
• WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 description 2
• 102100033639 Acetylcholinesterase Human genes 0.000 description 2
• 108010022752 Acetylcholinesterase Proteins 0.000 description 2
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
• 102400000948 Big gastrin Human genes 0.000 description 2
• 101800000285 Big gastrin Proteins 0.000 description 2
• 101710155857 C-C motif chemokine 2 Proteins 0.000 description 2
• 101710155833 C-C motif chemokine 8 Proteins 0.000 description 2
• 102000014914 Carrier Proteins Human genes 0.000 description 2
• 102000008186 Collagen Human genes 0.000 description 2
• 108010035532 Collagen Proteins 0.000 description 2
• 229920002307 Dextran Polymers 0.000 description 2
• 102000009109 Fc receptors Human genes 0.000 description 2
• 108010087819 Fc receptors Proteins 0.000 description 2
• 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
• 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
• 102000016359 Fibronectins Human genes 0.000 description 2
• 108010067306 Fibronectins Proteins 0.000 description 2
• 201000011240 Frontotemporal dementia Diseases 0.000 description 2
• 230000005526 G1 to G0 transition Effects 0.000 description 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
• 239000004471 Glycine Substances 0.000 description 2
• 229920002683 Glycosaminoglycan Polymers 0.000 description 2
• 102000009165 Gonadoliberin Human genes 0.000 description 2
• 108050000048 Gonadoliberin Proteins 0.000 description 2
• 101000946794 Homo sapiens C-C motif chemokine 8 Proteins 0.000 description 2
• 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
• 102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 2
• 206010061218 Inflammation Diseases 0.000 description 2
• 102000004877 Insulin Human genes 0.000 description 2
• 108090001061 Insulin Proteins 0.000 description 2
• 239000007836 KH2PO4 Substances 0.000 description 2
• 101710091439 Major capsid protein 1 Proteins 0.000 description 2
• 102000010909 Monoamine Oxidase Human genes 0.000 description 2
• 108010062431 Monoamine oxidase Proteins 0.000 description 2
• 241000699660 Mus musculus Species 0.000 description 2
• NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
• 102400001103 Neurotensin Human genes 0.000 description 2
• 101800001814 Neurotensin Proteins 0.000 description 2
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
• 102000002512 Orexin Human genes 0.000 description 2
• 206010031252 Osteomyelitis Diseases 0.000 description 2
• 102000004316 Oxidoreductases Human genes 0.000 description 2
• 108090000854 Oxidoreductases Proteins 0.000 description 2
• 238000012408 PCR amplification Methods 0.000 description 2
• 206010035226 Plasma cell myeloma Diseases 0.000 description 2
• XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 2
• 239000012722 SDS sample buffer Substances 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• 102000004338 Transferrin Human genes 0.000 description 2
• 108090000901 Transferrin Proteins 0.000 description 2
• 206010047513 Vision blurred Diseases 0.000 description 2
• 208000000208 Wet Macular Degeneration Diseases 0.000 description 2
• YVNQAIFQFWTPLQ-UHFFFAOYSA-O [4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylidene]-3-methylcyclohexa-2,5-dien-1-ylidene]-ethyl-[(3-sulfophenyl)methyl]azanium Chemical compound C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=C1 YVNQAIFQFWTPLQ-UHFFFAOYSA-O 0.000 description 2
• 238000002835 absorbance Methods 0.000 description 2
• OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
• 229960004373 acetylcholine Drugs 0.000 description 2
• 229940022698 acetylcholinesterase Drugs 0.000 description 2
• 230000001464 adherent effect Effects 0.000 description 2
• 238000001261 affinity purification Methods 0.000 description 2
• 230000032683 aging Effects 0.000 description 2
• 230000004075 alteration Effects 0.000 description 2
• 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 2
• 230000003942 amyloidogenic effect Effects 0.000 description 2
• 230000009833 antibody interaction Effects 0.000 description 2
• 230000009831 antigen interaction Effects 0.000 description 2
• 239000003963 antioxidant agent Substances 0.000 description 2
• 239000012298 atmosphere Substances 0.000 description 2
• 210000003719 b-lymphocyte Anatomy 0.000 description 2
• 230000008033 biological extinction Effects 0.000 description 2
• 239000012620 biological material Substances 0.000 description 2
• 239000000090 biomarker Substances 0.000 description 2
• 210000001775 bruch membrane Anatomy 0.000 description 2
• 238000010804 cDNA synthesis Methods 0.000 description 2
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
• 238000005119 centrifugation Methods 0.000 description 2
• HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
• 238000003776 cleavage reaction Methods 0.000 description 2
• 238000010367 cloning Methods 0.000 description 2
• 229920001436 collagen Polymers 0.000 description 2
• 238000012875 competitive assay Methods 0.000 description 2
• 230000000295 complement effect Effects 0.000 description 2
• 230000021615 conjugation Effects 0.000 description 2
• 230000006378 damage Effects 0.000 description 2
• 230000003247 decreasing effect Effects 0.000 description 2
• 229960005156 digoxin Drugs 0.000 description 2
• 229960003530 donepezil Drugs 0.000 description 2
• 238000001962 electrophoresis Methods 0.000 description 2
• 239000003797 essential amino acid Substances 0.000 description 2
• 235000020776 essential amino acid Nutrition 0.000 description 2
• DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
• 208000030533 eye disease Diseases 0.000 description 2
• 239000000835 fiber Substances 0.000 description 2
• 229940126864 fibroblast growth factor Drugs 0.000 description 2
• 210000005153 frontal cortex Anatomy 0.000 description 2
• 239000003517 fume Substances 0.000 description 2
• 229960003980 galantamine Drugs 0.000 description 2
• ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 2
• FMIHGWZLPSIAFY-WGFKALLTSA-N gastrin-34 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCC(N)=O)C(C)C)C1=CC=C(O)C=C1 FMIHGWZLPSIAFY-WGFKALLTSA-N 0.000 description 2
• 230000014509 gene expression Effects 0.000 description 2
• 229960002518 gentamicin Drugs 0.000 description 2
• 239000008103 glucose Substances 0.000 description 2
• ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
• 125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
• FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
• 230000003053 immunization Effects 0.000 description 2
• 230000002163 immunogen Effects 0.000 description 2
• 238000010348 incorporation Methods 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 229940125396 insulin Drugs 0.000 description 2
• 210000004558 lewy body Anatomy 0.000 description 2
• 150000002632 lipids Chemical class 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 239000011159 matrix material Substances 0.000 description 2
• AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 2
• BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 2
• 229960004640 memantine Drugs 0.000 description 2
• 244000005700 microbiome Species 0.000 description 2
• 239000000178 monomer Substances 0.000 description 2
• 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
• 235000019796 monopotassium phosphate Nutrition 0.000 description 2
• 238000010172 mouse model Methods 0.000 description 2
• 201000000050 myeloid neoplasm Diseases 0.000 description 2
• 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
• PCJGZPGTCUMMOT-ISULXFBGSA-N neurotensin Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 PCJGZPGTCUMMOT-ISULXFBGSA-N 0.000 description 2
• 238000006386 neutralization reaction Methods 0.000 description 2
• 229960003512 nicotinic acid Drugs 0.000 description 2
• 235000001968 nicotinic acid Nutrition 0.000 description 2
• 239000011664 nicotinic acid Substances 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 230000000050 nutritive effect Effects 0.000 description 2
• 108060005714 orexin Proteins 0.000 description 2
• OFNHNCAUVYOTPM-IIIOAANCSA-N orexin-a Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1NC(=O)[C@H](CO)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@H](C(N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N2)[C@@H](C)O)=O)CSSC1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NC(=O)CC1)C1=CNC=N1 OFNHNCAUVYOTPM-IIIOAANCSA-N 0.000 description 2
• 210000000056 organ Anatomy 0.000 description 2
• 239000012188 paraffin wax Substances 0.000 description 2
• 238000005897 peptide coupling reaction Methods 0.000 description 2
• 229920002401 polyacrylamide Polymers 0.000 description 2
• 229920000642 polymer Polymers 0.000 description 2
• 229940116357 potassium thiocyanate Drugs 0.000 description 2
• 230000036515 potency Effects 0.000 description 2
• 238000011533 pre-incubation Methods 0.000 description 2
• 230000002335 preservative effect Effects 0.000 description 2
• 230000035755 proliferation Effects 0.000 description 2
• 230000017854 proteolysis Effects 0.000 description 2
• 229940044551 receptor antagonist Drugs 0.000 description 2
• 239000002464 receptor antagonist Substances 0.000 description 2
• 238000011160 research Methods 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 210000001525 retina Anatomy 0.000 description 2
• 230000002441 reversible effect Effects 0.000 description 2
• 229960004136 rivastigmine Drugs 0.000 description 2
• 229920006395 saturated elastomer Polymers 0.000 description 2
• 230000007017 scission Effects 0.000 description 2
• 229910052709 silver Inorganic materials 0.000 description 2
• DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
• 230000009870 specific binding Effects 0.000 description 2
• 239000011550 stock solution Substances 0.000 description 2
• 238000003860 storage Methods 0.000 description 2
• 239000012536 storage buffer Substances 0.000 description 2
• 239000013589 supplement Substances 0.000 description 2
• 229960001685 tacrine Drugs 0.000 description 2
• YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 2
• 102000013498 tau Proteins Human genes 0.000 description 2
• 108010026424 tau Proteins Proteins 0.000 description 2
• 238000010257 thawing Methods 0.000 description 2
• 238000000954 titration curve Methods 0.000 description 2
• 231100000331 toxic Toxicity 0.000 description 2
• 230000002588 toxic effect Effects 0.000 description 2
• 239000011573 trace mineral Substances 0.000 description 2
• 235000013619 trace mineral Nutrition 0.000 description 2
• 239000012581 transferrin Substances 0.000 description 2
• 238000002371 ultraviolet--visible spectrum Methods 0.000 description 2
• 230000035899 viability Effects 0.000 description 2
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
• KYZWKYWGQFCRGN-OASOTCBPSA-N (2s)-2-aminopentanedioic acid;(2r)-2-(methylamino)butanedioic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O.OC(=O)[C@@H](N)CCC(O)=O KYZWKYWGQFCRGN-OASOTCBPSA-N 0.000 description 1
• BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
• SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
• KGLPWQKSKUVKMJ-UHFFFAOYSA-N 2,3-dihydrophthalazine-1,4-dione Chemical class C1=CC=C2C(=O)NNC(=O)C2=C1 KGLPWQKSKUVKMJ-UHFFFAOYSA-N 0.000 description 1
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 1
• SNKZJIOFVMKAOJ-UHFFFAOYSA-N 3-Aminopropanesulfonate Chemical compound NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 description 1
• OBWSOTREAMFOCQ-UHFFFAOYSA-N 4-(4-amino-3,5-dimethylphenyl)-2,6-dimethylaniline;hydrochloride Chemical compound Cl.CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 OBWSOTREAMFOCQ-UHFFFAOYSA-N 0.000 description 1
• XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
• QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
• YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
• TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
• 102100031126 6-phosphogluconolactonase Human genes 0.000 description 1
• 108010029731 6-phosphogluconolactonase Proteins 0.000 description 1
• 208000023761 AL amyloidosis Diseases 0.000 description 1
• 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 description 1
• HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
• 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
• 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
• 102100026882 Alpha-synuclein Human genes 0.000 description 1
• 102000004400 Aminopeptidases Human genes 0.000 description 1
• 108090000915 Aminopeptidases Proteins 0.000 description 1
• 102000001049 Amyloid Human genes 0.000 description 1
• 108010094108 Amyloid Proteins 0.000 description 1
• 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
• 208000007415 Anhedonia Diseases 0.000 description 1
• 206010002942 Apathy Diseases 0.000 description 1
• 206010003694 Atrophy Diseases 0.000 description 1
• 238000011725 BALB/c mouse Methods 0.000 description 1
• 241000894006 Bacteria Species 0.000 description 1
• 108090000363 Bacterial Luciferases Proteins 0.000 description 1
• 208000035143 Bacterial infection Diseases 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 101100091490 Caenorhabditis elegans hrp-1 gene Proteins 0.000 description 1
• 101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 description 1
• 229940127291 Calcium channel antagonist Drugs 0.000 description 1
• 108010078791 Carrier Proteins Proteins 0.000 description 1
• 208000002177 Cataract Diseases 0.000 description 1
• 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
• 208000011231 Crohn disease Diseases 0.000 description 1
• 229940123320 Cyclase inhibitor Drugs 0.000 description 1
• 102100037579 D-3-phosphoglycerate dehydrogenase Human genes 0.000 description 1
• IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 230000033616 DNA repair Effects 0.000 description 1
• 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
• 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
• CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
• 206010012239 Delusion Diseases 0.000 description 1
• LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
• 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
• 238000012286 ELISA Assay Methods 0.000 description 1
• 238000008157 ELISA kit Methods 0.000 description 1
• 229910052693 Europium Inorganic materials 0.000 description 1
• 206010016202 Familial Amyloidosis Diseases 0.000 description 1
• 206010016207 Familial Mediterranean fever Diseases 0.000 description 1
• 108090000331 Firefly luciferases Proteins 0.000 description 1
• BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
• 108010015133 Galactose oxidase Proteins 0.000 description 1
• 208000008069 Geographic Atrophy Diseases 0.000 description 1
• 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
• 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 1
• 102100022624 Glucoamylase Human genes 0.000 description 1
• 108010015776 Glucose oxidase Proteins 0.000 description 1
• 239000004366 Glucose oxidase Substances 0.000 description 1
• 108010018962 Glucosephosphate Dehydrogenase Proteins 0.000 description 1
• 108090000288 Glycoproteins Proteins 0.000 description 1
• 102000003886 Glycoproteins Human genes 0.000 description 1
• 239000007995 HEPES buffer Substances 0.000 description 1
• 208000004547 Hallucinations Diseases 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 208000017604 Hodgkin disease Diseases 0.000 description 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
• UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
• 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
• 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
• 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 description 1
• 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
• 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
• 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
• 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
• 102100034343 Integrase Human genes 0.000 description 1
• 101710144961 Interferon tau-1 Proteins 0.000 description 1
• 101710144950 Interferon tau-2 Proteins 0.000 description 1
• 101710144962 Interferon tau-3 Proteins 0.000 description 1
• 102100020873 Interleukin-2 Human genes 0.000 description 1
• 108010002350 Interleukin-2 Proteins 0.000 description 1
• 102000004388 Interleukin-4 Human genes 0.000 description 1
• 108090000978 Interleukin-4 Proteins 0.000 description 1
• 108090001005 Interleukin-6 Proteins 0.000 description 1
• 108010023244 Lactoperoxidase Proteins 0.000 description 1
• 102000045576 Lactoperoxidases Human genes 0.000 description 1
• 206010024229 Leprosy Diseases 0.000 description 1
• 229910013470 LiC1 Inorganic materials 0.000 description 1
• 208000010415 Low Vision Diseases 0.000 description 1
• 108060001084 Luciferase Proteins 0.000 description 1
• DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
• 229940123313 MCP-1 antagonist Drugs 0.000 description 1
• 241000282553 Macaca Species 0.000 description 1
• 108010026217 Malate Dehydrogenase Proteins 0.000 description 1
• 102000018697 Membrane Proteins Human genes 0.000 description 1
• 108010052285 Membrane Proteins Proteins 0.000 description 1
• 206010063341 Metamorphopsia Diseases 0.000 description 1
• 102000016943 Muramidase Human genes 0.000 description 1
• 108010014251 Muramidase Proteins 0.000 description 1
• 208000029578 Muscle disease Diseases 0.000 description 1
• KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
• 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
• 108010008881 NBI 5788 Proteins 0.000 description 1
• 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
• 102000003729 Neprilysin Human genes 0.000 description 1
• 108090000028 Neprilysin Proteins 0.000 description 1
• 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 1
• 108010032605 Nerve Growth Factor Receptors Proteins 0.000 description 1
• 102000008763 Neurofilament Proteins Human genes 0.000 description 1
• 108010088373 Neurofilament Proteins Proteins 0.000 description 1
• 206010029350 Neurotoxicity Diseases 0.000 description 1
• 206010061323 Optic neuropathy Diseases 0.000 description 1
• 229930012538 Paclitaxel Natural products 0.000 description 1
• 102000035195 Peptidases Human genes 0.000 description 1
• 108091005804 Peptidases Proteins 0.000 description 1
• 208000037581 Persistent Infection Diseases 0.000 description 1
• 108010004729 Phycoerythrin Proteins 0.000 description 1
• 102000012412 Presenilin-1 Human genes 0.000 description 1
• 108010036933 Presenilin-1 Proteins 0.000 description 1
• 206010036673 Primary amyloidosis Diseases 0.000 description 1
• 239000004365 Protease Substances 0.000 description 1
• 102100031674 Protein-L-isoaspartate(D-aspartate) O-methyltransferase Human genes 0.000 description 1
• 208000028017 Psychotic disease Diseases 0.000 description 1
• 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
• 241000700159 Rattus Species 0.000 description 1
• 108020004511 Recombinant DNA Proteins 0.000 description 1
• 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
• 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
• 229920005654 Sephadex Polymers 0.000 description 1
• 239000012507 Sephadex™ Substances 0.000 description 1
• 102100028656 Sigma non-opioid intracellular receptor 1 Human genes 0.000 description 1
• 101710104750 Sigma non-opioid intracellular receptor 1 Proteins 0.000 description 1
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
• BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
• 206010041243 Social avoidant behaviour Diseases 0.000 description 1
• 206010043114 Tangentiality Diseases 0.000 description 1
• 206010044221 Toxic encephalopathy Diseases 0.000 description 1
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
• 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
• 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
• 102400000757 Ubiquitin Human genes 0.000 description 1
• 108090000848 Ubiquitin Proteins 0.000 description 1
• 108010092464 Urate Oxidase Proteins 0.000 description 1
• 108010046334 Urease Proteins 0.000 description 1
• 206010047571 Visual impairment Diseases 0.000 description 1
• 108010093894 Xanthine oxidase Proteins 0.000 description 1
• 102100033220 Xanthine oxidase Human genes 0.000 description 1
• HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
• 230000005856 abnormality Effects 0.000 description 1
• 230000009471 action Effects 0.000 description 1
• 230000004913 activation Effects 0.000 description 1
• 239000007825 activation reagent Substances 0.000 description 1
• 239000012190 activator Substances 0.000 description 1
• 229960002916 adapalene Drugs 0.000 description 1
• 239000000654 additive Substances 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 229960000548 alemtuzumab Drugs 0.000 description 1
• 230000036626 alertness Effects 0.000 description 1
• 108090000185 alpha-Synuclein Proteins 0.000 description 1
• VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
• 125000003277 amino group Chemical group 0.000 description 1
• 229960003896 aminopterin Drugs 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• 230000003321 amplification Effects 0.000 description 1
• 230000006933 amyloid-beta aggregation Effects 0.000 description 1
• 230000003941 amyloidogenesis Effects 0.000 description 1
• 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
• 230000002424 anti-apoptotic effect Effects 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 239000007798 antifreeze agent Substances 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 201000007201 aphasia Diseases 0.000 description 1
• 238000013459 approach Methods 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 230000037444 atrophy Effects 0.000 description 1
• 239000005667 attractant Substances 0.000 description 1
• 239000003693 atypical antipsychotic agent Substances 0.000 description 1
• 229940127236 atypical antipsychotics Drugs 0.000 description 1
• 230000002567 autonomic effect Effects 0.000 description 1
• 208000022362 bacterial infectious disease Diseases 0.000 description 1
• 210000002469 basement membrane Anatomy 0.000 description 1
• 230000006399 behavior Effects 0.000 description 1
• 230000003542 behavioural effect Effects 0.000 description 1
• 230000009286 beneficial effect Effects 0.000 description 1
• 229940049706 benzodiazepine Drugs 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 108091007737 beta-secretases Proteins 0.000 description 1
• 108091008324 binding proteins Proteins 0.000 description 1
• 238000010876 biochemical test Methods 0.000 description 1
• 230000000035 biogenic effect Effects 0.000 description 1
• 230000033228 biological regulation Effects 0.000 description 1
• 238000005415 bioluminescence Methods 0.000 description 1
• 230000029918 bioluminescence Effects 0.000 description 1
• 238000013378 biophysical characterization Methods 0.000 description 1
• 238000001574 biopsy Methods 0.000 description 1
• 150000001615 biotins Chemical class 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 229940098773 bovine serum albumin Drugs 0.000 description 1
• UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
• 210000004899 c-terminal region Anatomy 0.000 description 1
• 239000000480 calcium channel blocker Substances 0.000 description 1
• 238000004364 calculation method Methods 0.000 description 1
• 238000011088 calibration curve Methods 0.000 description 1
• 229940112129 campath Drugs 0.000 description 1
• 150000001720 carbohydrates Chemical class 0.000 description 1
• 235000014633 carbohydrates Nutrition 0.000 description 1
• 150000001768 cations Chemical class 0.000 description 1
• 238000012832 cell culture technique Methods 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 230000001413 cellular effect Effects 0.000 description 1
• 210000004720 cerebrum Anatomy 0.000 description 1
• 230000003196 chaotropic effect Effects 0.000 description 1
• 238000012512 characterization method Methods 0.000 description 1
• 239000002738 chelating agent Substances 0.000 description 1
• 235000012000 cholesterol Nutrition 0.000 description 1
• 230000001713 cholinergic effect Effects 0.000 description 1
• 238000004587 chromatography analysis Methods 0.000 description 1
• 208000037976 chronic inflammation Diseases 0.000 description 1
• 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
• 238000002983 circular dichroism Methods 0.000 description 1
• 229960004170 clozapine Drugs 0.000 description 1
• QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
• 230000004186 co-expression Effects 0.000 description 1
• 230000019771 cognition Effects 0.000 description 1
• 230000003930 cognitive ability Effects 0.000 description 1
• 239000002299 complementary DNA Substances 0.000 description 1
• IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 1
• 230000001268 conjugating effect Effects 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 239000000470 constituent Substances 0.000 description 1
• 239000000356 contaminant Substances 0.000 description 1
• 230000002596 correlated effect Effects 0.000 description 1
• 230000002089 crippling effect Effects 0.000 description 1
• 238000005138 cryopreservation Methods 0.000 description 1
• 238000005520 cutting process Methods 0.000 description 1
• 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
• 239000002852 cysteine proteinase inhibitor Substances 0.000 description 1
• 231100000433 cytotoxic Toxicity 0.000 description 1
• 230000001472 cytotoxic effect Effects 0.000 description 1
• 125000001295 dansyl group Chemical group [H]C1=C([H])C(N(C([H])([H])[H])C([H])([H])[H])=C2C([H])=C([H])C([H])=C(C2=C1[H])S(*)(=O)=O 0.000 description 1
• 238000000354 decomposition reaction Methods 0.000 description 1
• 230000007547 defect Effects 0.000 description 1
• 230000006735 deficit Effects 0.000 description 1
• 230000007850 degeneration Effects 0.000 description 1
• 230000003111 delayed effect Effects 0.000 description 1
• 231100000868 delusion Toxicity 0.000 description 1
• 210000001947 dentate gyrus Anatomy 0.000 description 1
• 230000000779 depleting effect Effects 0.000 description 1
• 239000003599 detergent Substances 0.000 description 1
• 230000006866 deterioration Effects 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• 229940002658 differin Drugs 0.000 description 1
• LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 description 1
• LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
• QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 238000009509 drug development Methods 0.000 description 1
• 238000007877 drug screening Methods 0.000 description 1
• 208000011325 dry age related macular degeneration Diseases 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 230000005684 electric field Effects 0.000 description 1
• 230000008030 elimination Effects 0.000 description 1
• 238000003379 elimination reaction Methods 0.000 description 1
• 230000007613 environmental effect Effects 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 210000000981 epithelium Anatomy 0.000 description 1
• 125000004185 ester group Chemical group 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 238000001704 evaporation Methods 0.000 description 1
• 230000008020 evaporation Effects 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 239000012530 fluid Substances 0.000 description 1
• GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
• 238000013534 fluorescein angiography Methods 0.000 description 1
• 239000007850 fluorescent dye Substances 0.000 description 1
• 210000000245 forearm Anatomy 0.000 description 1
• 239000012595 freezing medium Substances 0.000 description 1
• 210000001652 frontal lobe Anatomy 0.000 description 1
• 230000005714 functional activity Effects 0.000 description 1
• 108091007739 gamma-secretases Proteins 0.000 description 1
• 102000038383 gamma-secretases Human genes 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 230000001295 genetical effect Effects 0.000 description 1
• 229940116332 glucose oxidase Drugs 0.000 description 1
• 235000019420 glucose oxidase Nutrition 0.000 description 1
• 239000003825 glutamate receptor antagonist Substances 0.000 description 1
• 235000011187 glycerol Nutrition 0.000 description 1
• 239000003102 growth factor Substances 0.000 description 1
• 208000017105 hereditary amyloidosis Diseases 0.000 description 1
• 125000000623 heterocyclic group Chemical group 0.000 description 1
• 239000003395 histamine H3 receptor antagonist Substances 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 230000008076 immune mechanism Effects 0.000 description 1
• 238000002649 immunization Methods 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 229940127121 immunoconjugate Drugs 0.000 description 1
• 238000001114 immunoprecipitation Methods 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 229940125721 immunosuppressive agent Drugs 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 230000002779 inactivation Effects 0.000 description 1
• 210000003000 inclusion body Anatomy 0.000 description 1
• 230000002757 inflammatory effect Effects 0.000 description 1
• 230000005764 inhibitory process Effects 0.000 description 1
• 229910052500 inorganic mineral Inorganic materials 0.000 description 1
• 108700027921 interferon tau Proteins 0.000 description 1
• 229940028885 interleukin-4 Drugs 0.000 description 1
• 238000011835 investigation Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 229940057428 lactoperoxidase Drugs 0.000 description 1
• 238000012886 linear function Methods 0.000 description 1
• 238000012417 linear regression Methods 0.000 description 1
• 230000007774 longterm Effects 0.000 description 1
• 231100000864 loss of vision Toxicity 0.000 description 1
• 208000018769 loss of vision Diseases 0.000 description 1
• 230000004303 low vision Effects 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 229960000274 lysozyme Drugs 0.000 description 1
• 239000004325 lysozyme Substances 0.000 description 1
• 235000010335 lysozyme Nutrition 0.000 description 1
• 229940092110 macugen Drugs 0.000 description 1
• 230000014759 maintenance of location Effects 0.000 description 1
• 239000003550 marker Substances 0.000 description 1
• 238000004949 mass spectrometry Methods 0.000 description 1
• 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 description 1
• 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 230000010534 mechanism of action Effects 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 206010027175 memory impairment Diseases 0.000 description 1
• 239000002207 metabolite Substances 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 108010029942 microperoxidase Proteins 0.000 description 1
• 210000002161 motor neuron Anatomy 0.000 description 1
• 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
• 230000003551 muscarinic effect Effects 0.000 description 1
• 210000000663 muscle cell Anatomy 0.000 description 1
• 210000001087 myotubule Anatomy 0.000 description 1
• UPSFMJHZUCSEHU-JYGUBCOQSA-N n-[(2s,3r,4r,5s,6r)-2-[(2r,3s,4r,5r,6s)-5-acetamido-4-hydroxy-2-(hydroxymethyl)-6-(4-methyl-2-oxochromen-7-yl)oxyoxan-3-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide Chemical compound CC(=O)N[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](NC(C)=O)[C@H](OC=2C=C3OC(=O)C=C(C)C3=CC=2)O[C@@H]1CO UPSFMJHZUCSEHU-JYGUBCOQSA-N 0.000 description 1
• 229960005027 natalizumab Drugs 0.000 description 1
• 230000001423 neocortical effect Effects 0.000 description 1
• 210000002241 neurite Anatomy 0.000 description 1
• 230000000926 neurological effect Effects 0.000 description 1
• 230000003557 neuropsychological effect Effects 0.000 description 1
• 231100000189 neurotoxic Toxicity 0.000 description 1
• 230000002887 neurotoxic effect Effects 0.000 description 1
• 231100000228 neurotoxicity Toxicity 0.000 description 1
• 230000007135 neurotoxicity Effects 0.000 description 1
• 239000002858 neurotransmitter agent Substances 0.000 description 1
• 230000007935 neutral effect Effects 0.000 description 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
• 238000010899 nucleation Methods 0.000 description 1
• 238000003199 nucleic acid amplification method Methods 0.000 description 1
• 210000004940 nucleus Anatomy 0.000 description 1
• 229960005017 olanzapine Drugs 0.000 description 1
• KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 1
• 208000020911 optic nerve disease Diseases 0.000 description 1
• 229940043515 other immunoglobulins in atc Drugs 0.000 description 1
• 238000007254 oxidation reaction Methods 0.000 description 1
• 230000036542 oxidative stress Effects 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052760 oxygen Inorganic materials 0.000 description 1
• 229960001592 paclitaxel Drugs 0.000 description 1
• 230000036961 partial effect Effects 0.000 description 1
• 230000001575 pathological effect Effects 0.000 description 1
• 229940005014 pegaptanib sodium Drugs 0.000 description 1
• 108010091748 peptide A Proteins 0.000 description 1
• 239000000813 peptide hormone Substances 0.000 description 1
• 230000002093 peripheral effect Effects 0.000 description 1
• 230000035699 permeability Effects 0.000 description 1
• 150000003904 phospholipids Chemical class 0.000 description 1
• 230000000649 photocoagulation Effects 0.000 description 1
• 238000002428 photodynamic therapy Methods 0.000 description 1
• 239000002504 physiological saline solution Substances 0.000 description 1
• RMHMFHUVIITRHF-UHFFFAOYSA-N pirenzepine Chemical compound C1CN(C)CCN1CC(=O)N1C2=NC=CC=C2NC(=O)C2=CC=CC=C21 RMHMFHUVIITRHF-UHFFFAOYSA-N 0.000 description 1
• 229960004633 pirenzepine Drugs 0.000 description 1
• 230000001242 postsynaptic effect Effects 0.000 description 1
• 230000001323 posttranslational effect Effects 0.000 description 1
• 239000000843 powder Substances 0.000 description 1
• 238000001556 precipitation Methods 0.000 description 1
• 238000004094 preconcentration Methods 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• 230000004647 pro-inflammatory pathway Effects 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 239000013587 production medium Substances 0.000 description 1
• 230000002250 progressing effect Effects 0.000 description 1
• 208000037821 progressive disease Diseases 0.000 description 1
• 230000000750 progressive effect Effects 0.000 description 1
• MGNVWUDMMXZUDI-UHFFFAOYSA-N propane-1,3-disulfonic acid Chemical compound OS(=O)(=O)CCCS(O)(=O)=O MGNVWUDMMXZUDI-UHFFFAOYSA-N 0.000 description 1
• 230000022558 protein metabolic process Effects 0.000 description 1
• 230000004850 protein–protein interaction Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 229940076788 pyruvate Drugs 0.000 description 1
• 150000005839 radical cations Chemical class 0.000 description 1
• 229910052761 rare earth metal Inorganic materials 0.000 description 1
• 150000002910 rare earth metals Chemical class 0.000 description 1
• 239000011541 reaction mixture Substances 0.000 description 1
• 239000000018 receptor agonist Substances 0.000 description 1
• 229940044601 receptor agonist Drugs 0.000 description 1
• 230000000306 recurrent effect Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 230000027756 respiratory electron transport chain Effects 0.000 description 1
• 230000002207 retinal effect Effects 0.000 description 1
• 238000010839 reverse transcription Methods 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 206010039073 rheumatoid arthritis Diseases 0.000 description 1
• PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
• 230000000630 rising effect Effects 0.000 description 1
• 229960001534 risperidone Drugs 0.000 description 1
• RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 1
• 239000012898 sample dilution Substances 0.000 description 1
• 238000003345 scintillation counting Methods 0.000 description 1
• 238000012106 screening analysis Methods 0.000 description 1
• 230000003248 secreting effect Effects 0.000 description 1
• 210000004739 secretory vesicle Anatomy 0.000 description 1
• 230000035945 sensitivity Effects 0.000 description 1
• 230000000862 serotonergic effect Effects 0.000 description 1
• 238000007086 side reaction Methods 0.000 description 1
• 230000011664 signaling Effects 0.000 description 1
• 239000004332 silver Substances 0.000 description 1
• 208000019116 sleep disease Diseases 0.000 description 1
• 208000020685 sleep-wake disease Diseases 0.000 description 1
• 238000010583 slow cooling Methods 0.000 description 1
• 210000000813 small intestine Anatomy 0.000 description 1
• 150000003384 small molecules Chemical class 0.000 description 1
• 239000001488 sodium phosphate Substances 0.000 description 1
• 235000011008 sodium phosphates Nutrition 0.000 description 1
• 229940054269 sodium pyruvate Drugs 0.000 description 1
• 239000008279 sol Substances 0.000 description 1
• 239000007787 solid Substances 0.000 description 1
• 238000009987 spinning Methods 0.000 description 1
• 210000004989 spleen cell Anatomy 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 230000004936 stimulating effect Effects 0.000 description 1
• 238000003756 stirring Methods 0.000 description 1
• 238000013337 sub-cultivation Methods 0.000 description 1
• 230000001629 suppression Effects 0.000 description 1
• 239000000725 suspension Substances 0.000 description 1
• 230000000946 synaptic effect Effects 0.000 description 1
• RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
• 210000003478 temporal lobe Anatomy 0.000 description 1
• MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
• 229940124597 therapeutic agent Drugs 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 229950010980 tiplimotide Drugs 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000009261 transgenic effect Effects 0.000 description 1
• 230000007704 transition Effects 0.000 description 1
• 108010018276 trimethylguanosine synthase Proteins 0.000 description 1
• RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
• 201000008827 tuberculosis Diseases 0.000 description 1
• 230000000381 tumorigenic effect Effects 0.000 description 1
• VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
• 229960005486 vaccine Drugs 0.000 description 1
• 210000003462 vein Anatomy 0.000 description 1
• 208000029257 vision disease Diseases 0.000 description 1
• 230000004304 visual acuity Effects 0.000 description 1
• 230000000007 visual effect Effects 0.000 description 1
• 238000012800 visualization Methods 0.000 description 1
• 239000011701 zinc Substances 0.000 description 1
• 229910052725 zinc Inorganic materials 0.000 description 1
• 229960000607 ziprasidone Drugs 0.000 description 1
• MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 description 1